resulted in small changes in the reported Hb fractions as well. Although this region of the spectrum would appear to be useful for differentiating MetHb from the other fractions, it introduced unwanted variability in the results. Avoiding this variable region of the Hb spectrum is one of the reasons that led us to select a different set of 10 wavelengths for the new 800 Series COoximeter.
Although it is customary to use the standard error or variance of observations as weighting factors for leastsquares analysis, it is often difficult to measure or estimate appropriate weighting factors to be used in real applications. Such is the case with CO-oximetry. As Yukawa et al. suggest, the standard error cannot be determined before the measurement because it depends on the actual concentrations of the components being measured. As they also suggest, the standard error could be estimated from measurements on donor samples and then applied to unknown samples in some iterative scheme. However, such an approach can account for only systematic errors in the measurement of absorbances and the variability in wavelength.
Our experience shows that for the measurement of typical blood samples, i.e., samples that are fresh and free of interfering substances and contamination, weighting factors of 1.0 yield both precise and accurate results. The systematic errors that affect all measurements in some measurable or estimatable manner have been minimized. It is the errors resulting from exceptional conditions such as interfering substances and improper preanalytical sample handling that cause the majority of inaccuracy and imprecision. Thus, our approach has been to select wavelengths that avoid many common interferents and minimize susceptibility to minor variations in wavelength.
Of course, it is not possible to avoid all interferents, so detection and correction algorithms have been devised for some known interferents such as lipid, SulfHb, CNMetHb, and methylene blue. For samples that contain uncharacterized interferents, the overdetermined measurement affords a "quality-of-fit index" that is used to detect the presence of unknown interferents and flag the samples with the message, "If blood, question data."
Yukawa et al. have clearly outlined the mathematics behind CO-oximetry measurements with overdetermined systems. However, we feel that the wider system issues of wavelength selection and detection of atypical samples also play an equally vital role in the performance of COoximeters. Hopefully this discussion has helped to enlighten users in regard to the characteristics and analytical limitations of present-day COoximeters.
Jacques A. Brunelle
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Chronic Increased Serum Lipase in a Patient with Suspected Pancreatic Adenocarcinoma
To the Editor: Donnelly et al. [1] described in this journal a patient similar to one studied by us. Our patient, a 57-year-old man, presented with cutaneous lesions in his legs, characterized by lobular panniculitis (PN) with fat necrosis and ghost cells. His serum lipase was 12 255 U/L at 25°C (by a turbidimetric method from Boehringer Mannheim, Mannheim, Germany; upper reference limit, 200 U/L). Surprisingly, his serum and urine amylase activities were not increased, and hepatic and renal function appeared to be normal upon admission. Three weeks later, his serum lipase was 11 141 U/L, and amylase remained within reference limits. Ultrasonography and computed tomography (CT) revealed a nodular lesion in his liver (13 ϫ 10 ϫ 15 cm). These features, combined with high lipase activity, led us to consider a pancreatic carcinoma with liver metastasis. However, two additional CT scans Ͼ2 weeks later showed no pancreatic abnormality. Histopathological analysis of needle aspirate from a liver nodule showed a papillary differentiated adenocarcinoma. Intestinal cancers were searched for but not found. Concentrations of carcinoembryonic antigen, CA 19.9, and CA 19.5 were within reference limits. Only ␣-fetoprotein was high (1075 g/L; upper reference limit: 20 g/L), consistent with hepatoma (although it can also be increased less dramatically in pancreatic carcinoma) [2] . Lipase activity was still increased 5 weeks after hospitalization (24 800 U/L), and activities of hepatic enzymes increased until the patient's death 3 months after presentation. Two weeks before his death, ultrasonography revealed a small, hypoechogenic solid node (2.3 ϫ 2.8 cm) in the body of the pancreas, and the patient was sent to our reference center for treatment. Postmortem examination could not be performed.
To account for the high lipase activity, we tested for several possibilities in blood samples obtained from the patient during hospitalization and stored at Ϫ20°C until assay: (a) analytical or physiological effects of drug origin; (b) the presence of macrolipase; and (c) the presence of lipase isoforms (and their pattern). Drug effects [3] were excluded by history. The diagnosis of macrolipasemia was not pursued because Ͻ2% of the activity in the supernatant was lost (decreasing from 15 268 to 14 960 U/L) after precipitation with polyethylene glycol as described for macroamylase screening [4] . Sera of patients with acute pancreatitis submitted to the same procedure showed a decrease in lipase activity of Ͻ20%. A decrease of Ͼ73% of amylase activity is generally required before the presence of macroamylase is considered. The precipitation of immunoglobulins after treatment with polyethylene gly-col was confirmed by assaying the supernatant for immunoglobulins.
To assay lipase isoforms, we followed the method proposed by Lott and Lu [5] , as modified by Donnelly et al. [1] . For controls, we used sera from patients with acute pancreatitis, in which L1 and L2 isoforms are usually present in equal amounts [5] . Undiluted serum from our patient showed the presence of trace amounts of L1 and a large spot at the previously described L2-L3 position [1, 5] (Fig. 1) . In diluted serum from the patient, a clear band appeared in the L2 zone. Proximity between L2 and L3 (carboxyl ester lipase) has been described, but our band is not L3 because the quantitative turbidimetric method we used does not detect carboxyl ester lipase activity [6] . Accordingly, if only one band appeared in the L2-L3 zone, it could not be L3. Moreover, in our case, after incubation for 20 min at 56°C, the patient's lipase activity changed from 11 000 U/L to 42 U/L, in agreement with the previously described thermolability of pancreatic isoforms [7] .
Our patient presented with an adenocarcinoma associated with high serum lipase activity, similar to the case reported by Donnelly et al. Nowadays, the diagnostic role for lipase isoforms is not clear [6] . In their series, Lott and Lu described the presence of L1 and L2 in pancreatic juice and tissue, duodenum extracts, and all acute pancreatitis sera, but not in healthy persons' sera. L2 is also described in sera of patients with gastric, small bowel, or large bowel diseases and in 70% of patients with liver or biliary tract disease, in which the pancreas may be affected by disorders of nearby organs [5] . Our unusual serum isoform pattern shows only L2, differing from that described by Donnelly et al., who detected only L1. Lott and Lu described a pattern similar to ours in two patients of their series, but both patients had increased amylase and their lipase was not as high.
In the only sample of pancreatic adenocarcinoma tissue they reported, Lott and Lu detected L3 alone, but we do not know the type of adenocarcinoma involved and it showed a low lipase activity of 2.83 U/g of tissue compared with 725 U/g in normal pancreatic tissue. To explain the presence of L1 in serum instead of the L1 and L2 isoforms detected in tumor tissue, Donnelly et al. proposed postranslational modification. The uncertain origin of the primary tumor, with no pancreatic alterations, and the immunohistochemical reactivity of a retroperitoneal node to prostate-specific antigen (PSA) led Donnelly et al. to think that a prostatic carcinoma could be the source of tumor. However, this PSA reactivity has also been described in acinar cell carcinoma of the pancreas [8] .
Interestingly, our patient developed PN as a paraneoplastic syndrome, in contrast to the case reported by Donnelly et al. Circulating lipase and other factors may be related to fat necrosis involved in pancreatic PN [9, 10] , but not every patient with high serum lipase activities develops this and, as far as we know, no isoform pattern has been studied in tissue and serum of patients with pancreatic PN. Our patient presented with a sort of PN pathognomonic for pancreatic disease [9, 11] . This case presents many aspects similar to those described previously [10, 12, 13] . The presence of adenocarcinoma, presumably pancreatic, with large hepatic metastases, pancreatic subcutaneous fat necrosis, and very high lipase activities accompanied by normal amylase activity is consistent with acinar adenocarcinoma of the pancreas, an uncommon entity [13] but so aggressive that it can lead to death with disseminated metastasis before its detection in the pancreas. Thus, the biochemical profile may be one of the first findings of this adenocarcinoma.
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Serum Amyloid A Remains at Physiological Concentrations in Coronary Atherosclerosis
To the Editor: Serum amyloid A (SAA), an apolipoprotein found in HDL, is a sensitive acute-phase reactant, its concentration in serum increasing up to 1000-fold in inflammatory disorders. Recently, greater attention has been paid to the roles of SAA in lipoprotein metabolism and atherogenesis under inflammatory conditions. Findings have shown that (a) SAA maintains the reverse cholesterol transport system [1 ] , (b) cells in the artery walls are able to express SAA [2 ] , and (c) SAA is present in atherosclerotic lesions [3 ] . However, there are no data regarding serum concentrations of SAA in the atherosclerotic diseases. Because the development of atherosclerotic lesions is accompanied by inflammation-like events, including release of cytokines capable of inducing SAA synthesis from cells in the artery walls [4 ] , a slight increase in serum concentrations of SAA seems possible.
Currently, a well-established latex agglutination nephelometric immunoassay is used to determine SAA [5 ] . The antibodies used in the assay system have no apparent cross-reactivity with a recently discovered constitutive isotype of SAA. This method has shown SAA to be a useful marker for viral infections, in which acute-phase reactants are not remarkably increased [6 ] . Here, we report our examination of serum SAA concentrations in patients with coronary atherosclerosis.
We studied 24 patients (17 men, 7 women; ages 39 -90) believed, on the basis of symptoms, stress electrocardiogram, and echocardiogram, to have angina pectoris or myocardial infarction. Stenosis in branches of the coronary artery was finally confirmed by angiography. These patients were followed-up conservatively as outpatients; serum samples were obtained during their regular appointments, when no apparent symptoms were noted.
The SAA values of the patients ranged from 1.5 to 5.1 mg/L. The number of affected coronary artery branches did not affect the SAA concentrations. The concentrations of HDL cholesterol were reduced (mean 30% lower) in these patients, but the SAA values were not related to the HDL cholesterol concentrations.
Using this method in a previous study [7 ] , we had also measured SAA in a large number of healthy subjects (n ϭ 452, ages 16 -70 years). In 95% of these healthy subjects, SAA values were Ͻ8.0 mg/L, and 85% showed concentrations Ͻ5.0 mg/L. Thus, the SAA concentrations in coronary atherosclerosis are indistinguishable from those seen physiologically. This suggests that local atherosclerotic changes as inflammatory stimuli may not reach the liver, the central organ of SAA synthesis; alternatively, perhaps locally produced SAA does not appear in the circulation.
